Healius Ltd

HLS: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|#bH?!#yLOCK|$yLOCK|$xX?mV<

Pathology Industry Growth Temporarily Hampered by Funding Cuts for Some Medicare Items

Medicare Australia statistics for benefits paid in core pathology for the four months to October 2025 increased by 2% on the prior corresponding period, a key revenue driver for Healius and Australian Clinical Labs, or ACL.

Sponsor Center